Exercise and Cancer: Why Metastasis Is a Trafficking Problem, Not Just Growth
Neurophysiologist Louisa Nicola walks through what cancer actually is, why metastasis — not the primary tumour — is what kills in solid tumours, and what the evidence says about physical activity across prevention, treatment and survivorship. Her core reframe: exercise is not a vague healthy habit but a repeated physiological signal that changes circulation, immunity, metabolism and muscle — the exact systems cancer interacts with at every stage.
Overview
This episode is built as a foundation-first explainer: without understanding the disease, the exercise evidence sounds like a claim rather than a conclusion. Nicola defines cancer as a breakdown of normal cellular rules — cells that ignore their brakes, avoid self-destruction and keep dividing — then separates initiation from the part that actually kills, which is metastasis.
Because cancer cells cannot teleport, they must enter circulation, survive a hostile journey, evade immune surveillance and colonise a new organ, which makes metastasis a survival and trafficking problem rather than a pure growth problem. From that base she reviews three separate buckets of evidence. Prevention comes from large prospective cohorts such as the NIH-AARP diet and health study of more than 150,000 adults, where higher activity tracked with lower incidence of several cancers even after adjusting for body mass index — a detail that points past weight loss toward insulin regulation, inflammation, immune surveillance and muscle metabolism.
Treatment evidence comes from randomised trials like the CARE trial in breast cancer patients on chemotherapy, where combined aerobic and resistance work improved function, reduced fatigue and helped preserve lean mass, and where better tolerance can mean staying on schedule rather than facing dose reductions. She also covers tumour perfusion and oxygenation, including a rectal cancer study in which people who exercised during neoadjuvant chemoradiation were more likely to reach a pathologic complete response.
The survivorship section is more nuanced: symptom and function benefits are robust, while recurrence and mortality data lean observational and are still being tested. She closes with mechanisms — shear stress on circulating tumour cells, immune mobilisation, insulin and IGF-1 signalling, muscle mass — plus honest limitations and a decision framework rather than a workout plan.
Key quotes
4Exercise is not a vague healthy habit in the context of cancer. It's a physiological signal that changes the environment that cancer cells are trying to survive in.
Cancer cells don't teleport. To metastasize, they have to physically enter circulation, survive a hostile journey, evade immune surveillance, and then successfully colonize a new environment.
As shear stress increased, survival of circulating tumor cells decreased.
Exercise does not work as a motivational concept. It works as a repeated physiological stress that remodels metabolism, immunity, circulation, and muscle.
Key ideas
9Cancer is a breakdown of cellular rules
Healthy cells have brakes, self-destruct mechanisms and they listen to their environment. Cancer begins when accumulated genetic and epigenetic changes let a cell ignore those rules and keep dividing.
The primary tumour is rarely the lethal part
Early breast or prostate cancer that stays local sits in tissue the body can survive without. Danger arrives when cells escape and establish in the liver, lungs, brain or bone — organs you cannot lose.
Why treatments succeed and why they fail
Treatment works when it removes the tumour or reduces burden enough for the immune system to handle the rest. It fails when microscopic disease was already present, cells were resistant, or spread had begun below the level of detection.
Large cohorts show a consistent prevention pattern
The NIH-AARP study followed more than 150,000 adults and linked high activity levels to lower incidence of several cancers, including colorectal and breast. Nurses' Health and Health Professionals data point the same direction.
The signal survives adjustment for body weight
Associations persisted after statistical adjustment for BMI, smoking, alcohol and diet. That points away from a simple weight-loss story and toward insulin regulation, chronic inflammation, immune surveillance and muscle metabolism.
The CARE trial and lean mass during chemotherapy
In breast cancer patients receiving chemotherapy, combined aerobic and resistance prescriptions improved physical function and reduced fatigue. Resistance work in particular helped preserve lean mass — metabolic reserve, not just strength.
Perfusion, oxygenation and treatment delivery
Tumours build abnormal blood vessels, and both drug delivery and radiation depend on flow and oxygen. Preclinical work suggests exercise can normalise tumour vasculature, and a rectal cancer study found higher rates of pathologic complete response among those who exercised during chemoradiation.
Shear stress and circulating tumour cells
In microfluidic studies, human cancer cells exposed to higher flow conditions showed reduced survival. Nicola links this to the blood shunting of very high intensity work, giving mechanistic plausibility to a less forgiving circulatory environment.
Immunity, metabolic signalling and muscle
Movement mobilises natural killer and cytotoxic T cells, improves insulin sensitivity, lowers IGF-1 signalling and reduces chronic inflammation. Low muscle mass, meanwhile, tracks with worse long-term outcomes in imaging-based prognostic work.
Practical takeaways
6- 1
Thirty minutes a day is the anchor number 2:50
Nicola cites evidence pointing to roughly 30 minutes of daily activity as the amount associated with down-regulating risk across 13 cancer types. It is a daily habit target, not a heroic one.
- 2
Pair aerobic work with resistance training 12:00
The prevention framing she lands on is meeting public health guidelines for moderate to vigorous activity plus added resistance work, because both aerobic capacity and muscle mass appear biologically protective.
- 3
During treatment the goal is preservation, not performance 21:00
Preserve muscle, function, sleep and mood. Guideline bodies including the American Society of Clinical Oncology now advise aerobic and resistance work for people in curative-intent treatment, always within medical guidance.
- 4
Survivorship is about rebuilding reserve 26:30
After treatment the body is deconditioned. Rebuilding muscle, strength and aerobic capacity restores physiological reserve and re-establishes the repeated immune and metabolic signalling that treatment interrupted.
- 5
Higher intensity has its own mechanism 29:50
The shear stress story rests on hard blood shunting at very high heart rates. Occasional bouts of genuinely high-intensity work may add something aerobic base training alone does not.
- 6
Respect the situations that need modification 34:30
Severe gastrointestinal toxicity, radiation-related skin injury, neuropathy and bone metastases all call for careful dosing and supervision. This is not a case for sending everyone to a boot camp.
Topics & chapters
15Why this conversation, done properly
Nicola rejects both the overly motivational and the overly simplistic versions of the exercise and cancer story. She sets up a foundation-first structure.
A personal fear
She contrasts her sense of control over Alzheimer's risk with her fear of cancer, which took her grandmother and her aunt, and which she sees daily in her clinical work.
What cancer actually is
Cancer in plain language: a cell that accumulates changes allowing it to ignore its brakes, avoid self-destruction and keep dividing when it shouldn't.
Local versus metastatic
Pieces of a tumour break off as circulating tumour cells, travel and colonise other organs. That spread, not the original tumour, is what makes solid tumours lethal.
Why treatments work and why they fail
Success means removing the tumour or reducing burden enough for immunity to hold the line. Failure often traces back to microscopic disease already present below detection.
A clear disclaimer
Nicola states she is a researcher, not an oncologist, and that anyone with a diagnosis should take these topics to their own medical team.
Prevention: the cohort evidence
The NIH-AARP study of more than 150,000 adults and other large cohorts link higher activity with lower incidence of colorectal, breast and other cancers.
Why statistical adjustment matters
Associations that survive adjustment for BMI show exercise is doing something beyond weight loss, pushing the explanation toward insulin, inflammation and immunity.
Not every cancer behaves the same
Colorectal, postmenopausal breast and endometrial cancers carry the most consistent evidence. Cancer is not one disease, so different tissues respond differently.
The CARE trial during chemotherapy
A landmark randomised trial combining aerobic and resistance exercise in breast cancer patients, testing function and treatment toxicity rather than mood or weight.
The psychological side of treatment
Trials such as ERASE included endpoints like fear of cancer progression. Improving a patient's sense of control over months or years of treatment is not a minor outcome.
Tolerance, dose intensity and guidelines
When patients cannot tolerate treatment, oncologists face dose reductions and delays. Better tolerance moved this from wellness to treatment support in formal guidance.
Tumour perfusion and oxygenation
Abnormal tumour vasculature limits drug delivery and radiation effect. Vascular normalisation offers a plausible route by which the same treatment becomes more effective.
Survivorship and recurrence
Function and symptom benefits are robust. Recurrence and mortality findings, including the colon cancer work in the New England Journal of Medicine, are largely observational.
Shear stress, immunity, metabolism and muscle
Mechanisms that make several steps of the metastatic process harder — then limitations, and a decision framework for prevention, treatment and survivorship.